Patented Medicine Prices Review Board

canada.ca Imported from official source

Regulator in Canada; financial publications from its own official source.

Publications 26

  1. Canada continues to approve and sell the highest-selling internationally approved new medicines – PMPRB’s latest report

    The Patented Medicine Prices Review Board (PMPRB) published the 10th edition of its annual Meds Entry Watch report today.

    Announcement Safety
  2. Federal Minister of Health tables the 2024 Annual Report of the Patented Medicine Prices Review Board

    Sales of patented medicines in Canada were $22.1 billion in 2024, a 10.9% increase over the year before.

    Announcement Safety
  3. Canadian public drug plan spending grew by $3.4 billion over 5 years, driven by use of higher-cost drugs

    The latest edition of the PMPRB CompassRx report shows that prescription drug expenditure for public drug plans grew by 7.4% in 2022/23 to reach $14.1 billion, compared to $13.2 billion in 2021/22.

    Announcement Safety
  4. PMPRB report reviews potential impact of new medicines on the Canadian market

    The Patented Medicine Prices Review Board published the 9th edition of its annual Meds Entry Watch report today.

    Announcement Safety
  5. Anie Perrault to lead PMPRB as Acting Chairperson

    Chairperson of the PMPRB, Mr. Thomas Digby has stepped down from his role, effective March 6, 2025.

    Announcement
  6. PMPRB report shows higher-cost medicines driving a 14.1% growth in private plan drug costs in 2023

    Report explores the drivers of growth in prescription drug costs for private drug plans

    Announcement Safety
  7. Federal Minister of Health tables the 2023 Annual Report of the Patented Medicine Prices Review Board

    86 new patented medicines were reported to the PMPRB in 2023

    Announcement Safety
  8. PMPRB report reviews new drugs and their potential impact on future drug spending in Canada

    The latest edition of Meds Pipeline Monitor provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may significantly impact clinical practice or drug spen...

    Announcement Safety
  9. PMPRB report examines availability and pricing of new medicines

    The Patented Medicine Prices Review Board published the 8th edition of its annual Meds Entry Watch report today.

    Announcement Safety
  10. Federal Minister of Health tables the 2022 Annual Report of the Patented Medicine Prices Review Board

    The Honourable Mark Holland, Federal Minister of Health, today tabled the 2022 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the Senate and the House of Comm...

    Announcement Safety
  11. PMPRB releases What We Learned Report from recent Policy Roundtable

    The Patented Medicine Prices Review Board (PMPRB) today published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December. The rep...

    Announcement Safety
  12. PMPRB release analyzes key cost pressures driving changes in public plan prescription drug expenditures

    PMPRB report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000.

    Announcement Finance
  13. PMPRB announces next steps in Guidelines consultation process

    The Patented Medicine Prices Review Board (PMPRB) will launch the first phase of consultations on its new Guidelines by inviting stakeholders to participate in a Policy Roundtable.

    Announcement Safety
  14. PMPRB report reveals most new medicines come to market with high treatment costs

    The Patented Medicine Prices Review Board (PMPRB) published today the 7th edition of its annual Meds Entry Watch report.

    Announcement Safety
  15. New report examines new drugs in the pipeline that may significantly impact future drug spending in Canada 

    Oncology continued to dominate the therapeutic mix of the drug pipeline in 2022.

    Announcement Safety
  16. Spending on antidiabetic drugs in Canada outpaced overall drug market 

    Canadian prices for top-selling antidiabetic drugs were higher than those in the PMPRB’s comparator countries from 2012 to 2021.

    Announcement Safety
  17. Patented Medicine Prices Review Board seeks applicants for vacant Board positions

    The Government of Canada is seeking applicants for the Vice Chairperson position and two Board Member positions on the Patented Medicine Prices Review Board by way of open, transparent, and merit-b...

    Announcement Safety
  18. Douglas Clark stepping down as Executive Director of the PMPRB 

    Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), has announced that he will be stepping down from that position after almost a decade at the PMPRB.

    Announcement
  19. Increased use of higher-cost medicines continues to put pressure on Canadian public drug plans

    A new Patented Medicine Prices Review Board (PMPRB) report finds that prescription drug expenditures by Canadian public drug plans increased by 4.2% in 2020-21, bringing annual spending to $12.3 bi...

    Announcement Safety
  20. Federal Minister of Health tables the 2021 Annual Report of the Patented Medicine Prices Review Board

    The Honourable Jean-Yves Duclos, Federal Minister of Health, tabled the 2021 Annual Report of the Patented Medicine Prices Review Board with the Clerks of the Senate and the House of Commons on Fri...

    Announcement Safety
  21. PMPRB Hearing Panel issues order in Procysbi case

    In an order dated October 13, 2022, the Hearing Panel directed Horizon to pay $22,028,977.26 to the Receiver General of Canada within 30 days of the date of the Order. It is the largest amount ever...

    Announcement
  22. Federal drug price watchdog consulting public on proposed changes to its pricing guidelines

    The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines today and launched a 60-day consultation period with stakeholders and interested members of the public.

    Announcement Safety
  23. PMPRB Hearing Panel issues decision in Procysbi case

    A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Procysbi, manufactured and marketed in Canada by Horizon Pharma.

    Announcement Safety

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.